Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.
View Top Employees from Flamingo Therapeutics| Website | https://www.flamingotx.com |
| Employees | 20 (14 on RocketReach) |
| Founded | 2019 |
| Industry | Biotechnology Research, Drug Discovery, Biotechnology |
Looking for a particular Flamingo Therapeutics employee's phone or email?
Flamingo Therapeutics Questions
A Robert Macleod is the Chief Scientific Officer, Senior Vice President Research and Development of Flamingo Therapeutics.
14 people are employed at Flamingo Therapeutics.
Top Flamingo Therapeutics Employees
-
5+
-
ViewA Robert Macleod
Chief Scientific Officer, Senior Vice President Research and Development at Flamingo Therapeutics
San Diego, California, United States15 -
ViewSusan MacIntyre
Vice President Clinical Operations at Flamingo Therapeutics
Merion Station, PA, US55 -
5+5+
-
ViewFloor Stam
Co-founder, VP of Corporate Development and Operations at Flamingo Therapeutics
Leuven, Flanders, BE21 -
View
Tiziana Girardi
Associate Director - Drug Discovery at Flamingo Therapeutics
Leuven, Flanders, BE2 -
ViewA Robert Macleod
Chief Scientific Officer, Senior Vice President Research and Development at Flamingo Therapeutics
San Diego, California, United States25+
Related Companies
